Admission Serum Bicarbonate Predicts Adverse Clinical Outcomes in Hospitalized Cirrhotic Patients

Table 2

Frequency of outcomes among the study cohort.

Outcome	Total (N = 2693)	SB < 14 (N = 66)	SB 14–17 (N = 227)	SB 18–21 (N = 662)	SB 22–25 (N = 1072)	SB 26–29 (N = 531)	SB 30–33 (N = 100)	SB >33 (N = 35)
Renal failure (AKI/HRS)^†	624 (23.2)	46 (69.7)	120 (52.9)	197 (29.8)	164 (15.3)	67 (12.6)	14 (14)	8 (22.9)
PSE^†	193 (7.2)	12 (18.2)	32 (14.1)	47 (7.1)	60 (5.6)	27 (5.1)	9 (9)	4 (11.4)
GIB^†	255 (9.5)	13 (19.7)	36 (15.9)	67 (10.1)	109 (10.2)	24 (4.5)	6 (6)	0 (0)
Ascites^†	518 (19.2)	19 (28.8)	66 (29.1)	152 (23)	176 (16.4)	77 (14.5)	12 (12)	8 (22.9)
SBP^†	173 (6.4)	10 (15.2)	27 (11.9)	51 (7.7)	55 (5.1)	21 (4.0)	6 (6)	3 (8.6)
ICU care^†	233 (8.7)	22 (33.3)	36 (15.9)	69 (10.4)	69 (6.4)	26 (4.9)	8 (8)	3 (8.6)
Death^†	172 (6.4)	11 (16.7)	37 (16.3)	49 (7.4)	50 (4.7)	17 (3.2)	7 (7)	1 (2.9)
Hospital LOS (days)^†	8.8 ± 10.9	14.2 ± 15.8	12.8 ± 13.7	10 ± 12.4	7.6 ± 9.2	7 ± 8.4	8.9 ± 13.9	9.9 ± 11

Values represented as count (column %) or mean (±SD). ^†Significant difference in frequency between SB groups ().SB, serum bicarbonate; AKI/HRS, acute kidney injury or hepatorenal syndrome; PSE, portosystemic encephalopathy; GIB, gastrointestinal bleed; SBP, spontaneous bacterial peritonitis; ICU, intensive care unit; LOS, length of stay.